Table 2. Case characteristics and fulfilment of the 2019 EULAR/ACR classification criteria items for SLE at time of diagnosis for the incident Southeast Norway SLE cohort during 2000–2017 (N=737).
| Cohort fulfilling2019 EULAR/ACR criteria | Cohort not fulfilling2019 EULAR/ACR criteria | ||||||
| TotalN=677 | Female N=574 | MaleN=103 | TotalN=60 | FemaleN=45 | MaleN=15 | ||
| Case characteristics | |||||||
| Adults, n (%) | 642 (94.8) | 546 (95.1) | 96 (93.2) | 59 (98.3) | 44 (97.8) | 15 (100) | |
| Mean age at diagnosis, years (SD) | 39.1 (16.6) | 37.8 (15.7) | 46.3 (19.3) | 44.2 (14.6) | 42.6 (14.6) | 49.1 (13.7) | |
| European descent, n (%) | 553 (81.7) | 460 (80.1) | 93 (90.3) | 56 (93.3) | 43 (95.6) | 13 (86.7) | |
| Cases meeting 1997 ACR criteria, n (%) | 558 (82.4) | 479 (83.4) | 79 (76.7) | 16 (26.7) | 13 (28.9) | 3 (20.0) | |
| 2019 EULAR/ACR criteria-items at time of diagnosis | P value† | ||||||
| ANA positive, n (%) | 677 (100) | 574 (100) | 103 (100) | 38 (63.3) | 30 (66.7) | 8 (53.3) | |
| Mean 2019 EULAR/ACR criteria points, n (SD) | 20.8 (7.4) | 20.7 (7.3) | 21.2 (7.7) | 10.9 (7.8) | 10.5 (8.0) | 12.2 (7.5) | |
| Constitutional, n (%) | 267 (39.4) | 225 (39.2) | 42 (40.8) | 9 (15.0) | 5 (11.1) | 4 (26.7) | Total: **Female: ** |
| Haematologic, n (%) | 328 (48.4) | 279 (48.6) | 49 (47.6) | 18 (30.0) | 13 (28.9) | 5 (33.3) | Total: *Female: * |
| Neuropsychiatric, n (%) | 16 (2.4) | 15 (2.6) | 1 (1.0) | 4 (6.7) | 3 (6.7) | 1 (6.7) | Total: * |
| Mucocutaneous, n (%) | 480 (70.9) | 426 (74.2) | 54 (52.4) | 38 (63.3) | 32 (71.1) | 6 (40.0) | |
| Serositis, n (%) | 139 (20.5) | 110 (19.2) | 29 (28.2) | 4 (6.7) | 2 (4.4) | 2 (13.3) | Total: *Female: * |
| Musculoskeletal, n (%) | 534 (78.9) | 459 (80.0) | 75 (72.8) | 26 (43.3) | 21 (46.7) | 5 (33.3) | Total: **Female: **Male: * |
| Renal, n (%) | 191 (28.2) | 144 (25.1) | 47 (45.6) | 11 (18.3) | 6 (13.3) | 5 (33.3) | |
| Anti-phospholipid antibodies, n (%) | 231 (34.1) | 203 (35.4) | 28 (272) | 13 (21.7) | 7 (15.6) | 6 (40.0) | Total: *Female: * |
| Complementary proteins, n (%) | 307 (45.3) | 258 (44.9) | 49 (47.6) | 12 (20) | 9 (20.0) | 3 (20.0) | Total: **Female: *Male: * |
| SLE-specific antibodies, n (%) | 513 (75.8) | 437 (76.1) | 76 (73.8) | 8 (13.3) | 6 (13.3) | 2 (13.3) | Total: **Female: **Male: ** |
1997 ACR criteria, 1997 American College of RheumatologyACR classification criteria for Systemic Lupus Erythematous; 2019 EULAR/ACR criteria, 2019 European Alliance of Associations for Rheumatology/American College of RheumatologyEULAR/ACR classification criteria for Systemic Lupus Erythematous; ANA, antinuclear antibodies; N, number of cases of the incident SLE population; n, number of cases; , standard deviation; § P-value for 2019 EULAR/ACR criteria fulfilment not fulfilment; *; **SLE.
p<0.05, **p<0.001.
P value for 2019 EULAR/ACR criteria fulfilment versus not fulfilment.
ANAantinuclear antibodiesEULAR/ACREuropean Alliance of Associations for Rheumatology/American College of Rheumatologynnumber of casesSDstandard deviationSLE, systemic lupus erythematosus